Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
| Autor: | Drorit Neumann, Moshe Mittelman, Natalia Golishevsky, Elizabeth Naparstek, Amos Cohen, Odelia Katz, Sara Prutchi-Sagiv, Howard S. Oster |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Antigens
Differentiation T-Lymphocyte Male medicine.medical_specialty Lymphocyte T cell T-Lymphocytes CD4-CD8 Ratio Lymphocyte Activation Immunophenotyping Hemoglobins Leukocyte Count Immune system CD28 Antigens Antigens CD hemic and lymphatic diseases Immunopathology Internal medicine medicine Humans CTLA-4 Antigen Lectins C-Type Erythropoietin Multiple myeloma Aged Hematology business.industry Interleukin-6 Middle Aged medicine.disease Antigens Differentiation Recombinant Proteins medicine.anatomical_structure Case-Control Studies Immunology Disease Progression Female business Multiple Myeloma Biomarkers Kidney disease medicine.drug |
| Zdroj: | British journal of haematology. 135(5) |
| ISSN: | 0007-1048 |
| Popis: | Erythropoietin (Epo) is the main growth regulator of red blood cells, and recombinant human erythropoietin (rHuEpo) is thus used in clinical practice for the treatment of anaemia, primarily in kidney disease and cancer. rHuEpo treatment was found to be associated with prolonged survival of multiple myeloma (MM) patients. This clinical observation was then supported by studies on murine myeloma models. It thus appeared that rHuEpo had an anti-myeloma effect, causally related to an immunomodulatory function of rHuEpo. The present study investigated whether rHuEpo-treated MM patients acquire improved immunological functions. Treatment with rHuEpo, prescribed for anaemia that occurs in advanced disease, was associated with effects on a variety of immunological parameters and functions. This was expressed in an actual normalisation of the CD4:CD8 cell ratio, enhanced T cell phytohaemagglutinin-mediated activation and proliferation potential, T cell expression of the costimulatory CD28 and inhibitory CTLA-4 molecules, as well as reduced interleukin-6 serum values to normal levels. Furthermore, it was demonstrated that immunological abnormalities manifest in patients even in the early stages of MM. Our findings thus suggest that rHuEpo treatment might be effective in the early stages of MM, before anaemia develops. It is expected that this would boost the immune system, consequently achieving an anti-myeloma function; affecting disease progression and improving the prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text